WO2003011008A3 - Therapeutic delivery compositions and methods of use thereof - Google Patents
Therapeutic delivery compositions and methods of use thereof Download PDFInfo
- Publication number
- WO2003011008A3 WO2003011008A3 PCT/US2002/024425 US0224425W WO03011008A3 WO 2003011008 A3 WO2003011008 A3 WO 2003011008A3 US 0224425 W US0224425 W US 0224425W WO 03011008 A3 WO03011008 A3 WO 03011008A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- therapeutic delivery
- delivery compositions
- compositions
- copolymers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003516253A JP2005500340A (en) | 2001-07-31 | 2002-07-31 | Composition for delivery for therapy and method of use thereof |
US10/485,610 US20040248833A1 (en) | 1991-03-19 | 2002-07-31 | Therapeutic delivery compositions and methods of use thereof |
EP02765919A EP1421170A2 (en) | 2001-07-31 | 2002-07-31 | Therapeutic delivery compositions and methods of use thereof |
CA002455843A CA2455843A1 (en) | 2001-07-31 | 2002-07-31 | Therapeutic delivery compositions and methods of use thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/919,504 | 2001-07-31 | ||
US09/919,504 US20020123476A1 (en) | 1991-03-19 | 2001-07-31 | Therapeutic delivery compositions and methods of use thereof |
US09/929,819 US6933286B2 (en) | 1991-03-19 | 2001-08-14 | Therapeutic delivery compositions and methods of use thereof |
US09/929,819 | 2001-08-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003011008A2 WO2003011008A2 (en) | 2003-02-13 |
WO2003011008A3 true WO2003011008A3 (en) | 2004-03-25 |
Family
ID=27129773
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/024425 WO2003011008A2 (en) | 1991-03-19 | 2002-07-31 | Therapeutic delivery compositions and methods of use thereof |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1421170A2 (en) |
JP (1) | JP2005500340A (en) |
CA (1) | CA2455843A1 (en) |
WO (1) | WO2003011008A2 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4902500A (en) * | 1987-11-27 | 1990-02-20 | Akzo N.V. | Stabilization of antibodies |
US5234683A (en) * | 1985-06-18 | 1993-08-10 | Emory University | Method of stimulating the immune system |
US5656611A (en) * | 1994-11-18 | 1997-08-12 | Supratek Pharma Inc. | Polynucleotide compositions |
US5824322A (en) * | 1995-08-21 | 1998-10-20 | Cytrx Corporation | Compositions and methods for growth promotion |
US6093391A (en) * | 1992-10-08 | 2000-07-25 | Supratek Pharma, Inc. | Peptide copolymer compositions |
US6359054B1 (en) * | 1994-11-18 | 2002-03-19 | Supratek Pharma Inc. | Polynucleotide compositions for intramuscular administration |
-
2002
- 2002-07-31 WO PCT/US2002/024425 patent/WO2003011008A2/en active Application Filing
- 2002-07-31 EP EP02765919A patent/EP1421170A2/en not_active Withdrawn
- 2002-07-31 CA CA002455843A patent/CA2455843A1/en not_active Abandoned
- 2002-07-31 JP JP2003516253A patent/JP2005500340A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5234683A (en) * | 1985-06-18 | 1993-08-10 | Emory University | Method of stimulating the immune system |
US4902500A (en) * | 1987-11-27 | 1990-02-20 | Akzo N.V. | Stabilization of antibodies |
US6093391A (en) * | 1992-10-08 | 2000-07-25 | Supratek Pharma, Inc. | Peptide copolymer compositions |
US5656611A (en) * | 1994-11-18 | 1997-08-12 | Supratek Pharma Inc. | Polynucleotide compositions |
US6359054B1 (en) * | 1994-11-18 | 2002-03-19 | Supratek Pharma Inc. | Polynucleotide compositions for intramuscular administration |
US5824322A (en) * | 1995-08-21 | 1998-10-20 | Cytrx Corporation | Compositions and methods for growth promotion |
Non-Patent Citations (2)
Title |
---|
DATABASE MEDLINE [online] 1986, PAHLSON ET AL.: "Curved rods related to Mobiluncus: phenotypes as defined by monoclonal antibodies; hybridoma generation and monoclonal antibody production", XP002964700, accession no. STN Database accession no. 1986-10657 * |
DATABASE MEDLINE [online] May 1989 (1989-05-01), WOODARD ET AL.: "Adjuvant activity of water insoluble surfactans", XP002964699, accession no. STN Database accession no. 89260215 * |
Also Published As
Publication number | Publication date |
---|---|
WO2003011008A2 (en) | 2003-02-13 |
JP2005500340A (en) | 2005-01-06 |
CA2455843A1 (en) | 2003-02-13 |
EP1421170A2 (en) | 2004-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003013437A3 (en) | Compositions and methods for the prevention and treatment of huntington's disease | |
WO2001048190A3 (en) | Therapeutic uses of lna-modified oligonucleotides | |
AU2001292881A1 (en) | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye | |
WO2005079195A3 (en) | Pyrazolopyridines and analogs thereof | |
EP1390472A4 (en) | Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv | |
AU3755900A (en) | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye | |
IL157652A (en) | Metalloproteinase inhibitors, compositions comprising them and uses thereof for the preparation of medicaments for treating diseases or conditions mediated by metalloproteinase enzymes | |
GB0128108D0 (en) | Therapeutic use | |
WO2004014312A3 (en) | Small-mer compositions and methods of use | |
WO2001070977A3 (en) | Fibroblast growth factor receptor-like molecules and uses thereof | |
WO2005002526A3 (en) | Method and compositions for treatment of viral infections | |
WO2004096842A3 (en) | Sars virus nucleotide and amino acid sequences and uses thereof | |
AU2003225281A1 (en) | Materials and methods for prevention and treatment of rna viral diseases | |
WO2004039957A3 (en) | Inhibition of gene expression using rna interfering agents | |
WO2003088899A3 (en) | Methods for the production of chimeric adeno-associated virus (aav) vectors, compositions of chimeric aav vectors, and methods of use thereof | |
WO2001068854A3 (en) | Fibroblast growth factor-like molecules and uses thereof | |
DE69732029D1 (en) | DNA-Containing VACCINES | |
AU2003287145A1 (en) | Interferon drug therapy for the treatment of viral diseases and liver fibrosis | |
WO2003059376A8 (en) | The use of il6r/il6 chimera in nerve cell regeneration | |
WO2004030631A3 (en) | Anti-cancer and anti-infectious disease compositions and methods for using same | |
WO2005019259A3 (en) | Variants of interleukin-1 receptor antagonist: compositions and uses thereof | |
WO2003011008A3 (en) | Therapeutic delivery compositions and methods of use thereof | |
WO2003099224A3 (en) | Antisense moodulation of kinesin-like 1 expression | |
WO2001024764A3 (en) | Cell targeting compositions and methods of using the same | |
AU2002341207A1 (en) | Use of 2'-5'-oligoadenylate synthetase and/or rnasel or nucleic acids encoding them for diagnosis, prophylaxis or treatment of wound healing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002329679 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2455843 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003516253 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002765919 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002765919 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10485610 Country of ref document: US |